All In Biotech

Drug Trial Radar · NCT07172867

A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM

A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study to Evaluate the Safety, Efficacy and Tolerability of Ofirnoflast (HT-6184) and Semaglutide in Obese or Overweight Participants With Type 2 Diabetes Mellitus (T2DM)

Last checked: Nov 19, 2026Latest source record: Feb 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Jan 6, 2026

Primary completion

Jan 23, 2026

Study completion Jan 23, 2026

Sponsor

Lead sponsor
Halia Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Sep 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of ofirnoflast in combination with semaglutide in comparison to semaglutide alone in obese participants with T2DM.

Conditions

  • Diabetes Mellitus, Type 2
  • Obesity

Interventions

  • HT-6184Drug

    2mg QD

  • HT-6184 Matching PlaceboDrug

    2mg QD

  • Semaglutide 1 mgDrug

    Semaglutide 1 mg, every week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess glycemic control using HbA1c (%)Time frame: From first dose through End of Study (up to 12 weeks per participant)
  2. Assess weight loss using body weight measurementsTime frame: From first dose through End of Study (up to 12 weeks per participant)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cleveland Clinic Abu Dhabi

    Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.